Inovio Pharmaceuticals (INO) Notes Payables (2010 - 2026)

Inovio Pharmaceuticals has disclosed Notes Payables across 17 years of filings, most recently posting $25.0 million for Q2 2026.

• In Q2 2026, Notes Payables rose 119.13% year-over-year to $25.0 million; the TTM figure through Jun 2026 stood at $25.0 million (up 119.13% YoY), while the FY2025 annual figure was $29.1 million, up 119.29% from the prior year.
• Notes Payables came in at $25.0 million for Q2 2026 at Inovio Pharmaceuticals, roughly flat from $24.9 million in the prior quarter.
• In the past five years, Notes Payables ranged from a high of $50.4 million in Q3 2025 to a low of $1.2 million in Q4 2022.
• Average Notes Payables over 5 years is $14.2 million, with a median of $10.5 million recorded in 2025.
• The largest YoY upside for Notes Payables was 232.31% in 2022 against a maximum downside of 24.53% in 2022.
• Over 5 years, Notes Payables stood at $1.2 million in 2022, then gained by 16.13% to $1.4 million in 2023, then jumped by 835.26% to $13.3 million in 2024, then surged by 119.29% to $29.1 million in 2025, then declined by 13.91% to $25.0 million in 2026.
• Per Business Quant data, the three most recent Notes Payables figures were $25.0 million in Q2 2026, $24.9 million in Q1 2026, and $29.1 million in Q4 2025.